» Articles » PMID: 20951504

Recurrence Patterns and Survival for Patients with Intermediate- and High-grade Myxofibrosarcoma

Overview
Specialties Oncology
Radiology
Date 2010 Oct 19
PMID 20951504
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Myxofibrosarcoma (MFS) is a rare sarcoma with a predilection for multiple local recurrences (LR), for which optimal treatment has not been defined. We reviewed our experience to determine the impact of surgery and radiation therapy (RT) on pattern of recurrence, limb salvage, and overall survival (OS).

Methods And Materials: Between 1995 and 2005, 36 patients with localized intermediate- or high-grade MFS were treated at our institution. Data on clinicopathologic features, treatments, and patient outcomes were reviewed and analyzed.

Results: Median age was 72.5 years (range, 42-96 years). Median tumor size was 7.5 cm, and 34 tumors (94%) were high grade. All patients underwent surgery at our institution, including re-resections in 20 patients (56%) after initial surgery elsewhere. Margins were microscopically positive in 9 patients (25%). RT was given to 28 patients (78%) pre - and/or postoperatively. After a median follow-up of 3.5 years (range, 0.4-12.4 years), 11 patients (31%) developed LR. There were no significant predictors for LR on univariate analysis, including margin status or use of RT. Limb salvage was ultimately achieved in only 5 of 11 LRs (45%) because of multiple subsequent LRs. Distant recurrence (DR) occurred in 6 patients (17%). Median and 4-year OS were 96 months and 65%, respectively. Seven patients (19%) died of tumor-related causes, 6 of whom had DRs. On univariate analysis, tumor size was associated with OS.

Conclusions: Despite aggressive surgery and RT, intermediate- and high-grade MFS are associated with a high rate of LR that adversely affects limb preservation. More aggressive local treatment strategies are necessary.

Citing Articles

Giant Myxofibrosarcoma in the Lower Limb: An Overview of Diagnostic and Clinical Management.

Ene R, Dimitriu A, Peride I, Tiglis M, Popescu E, Georgescu E Diagnostics (Basel). 2024; 14(12).

PMID: 38928713 PMC: 11202561. DOI: 10.3390/diagnostics14121298.


Myxofibrosarcoma: Outcomes, Prognostic Factors, and Role of Neoadjuvant Radiation Therapy.

Abdou M, Bogan A, Thangaiah J, Grover A, Ahmed S, Houdek M Adv Radiat Oncol. 2024; 9(6):101485.

PMID: 38681890 PMC: 11043815. DOI: 10.1016/j.adro.2024.101485.


A rare presentation of primary cardiac myxofibrosarcoma: Case report and literature review.

Soltani S, Garousi M, Mirzaee E, Koolaji S, Nazari H, Emami S Cancer Rep (Hoboken). 2024; 7(4):e2033.

PMID: 38600050 PMC: 11006601. DOI: 10.1002/cnr2.2033.


Epidemiology and survival factors of appendicular myxofibrosarcoma: a SEER-retrospective study.

Dahl V, Lee Y, Rate 4th W, Guertin M, Pretell-Mazzini J Rep Pract Oncol Radiother. 2024; 28(6):711-719.

PMID: 38515824 PMC: 10954266. DOI: 10.5603/rpor.97733.


Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution.

Pogkas A, Reichardt P, Tunn P, Niethard M, Werner M, Ghani S Oncologist. 2023; 29(4):e544-e552.

PMID: 38141181 PMC: 10994258. DOI: 10.1093/oncolo/oyad332.